The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Milovanov Iu.S.

Universitetskaia klinicheskaia bol'nitsa #3 (Klinika nefrologii, vnutrennikh i professional'nykh bolezneĭ im. E.M. Tareeva) Pervogo MGMU im. I.M. Sechenova Minzdrava Rossii

Fomin V.V.

I.M. Sechenov First State Moscow Medical University

Milovanova L.Iu.

Universitetskaia klinicheskaia bol'nitsa #3 (Klinika nefrologii, vnutrennikh i professional'nykh bolezneĭ im. E.M. Tareeva) Pervogo MGMU im. I.M. Sechenova Minzdrava Rossii

Difficulties in correcting hyperphosphatemia in patients with chronic renal failure. A place of noncalcium-containing phosphate-binding drugs

Authors:

Milovanov Iu.S., Fomin V.V., Milovanova L.Iu.

More about the authors

Journal: Therapeutic Archive. 2016;88(6): 95‑100

DOI: 10.17116/terarkh201688695-100

Views: 9479

Downloaded: 584

Download PDF (RU)
Contact the author
Table of contents

DIFFICULTIES IN CORRECTING HYPERPHOSPHATEMIA IN PATIENTS WITH CHRONIC RENAL FAILURE. A PLACE OF NONCALCIUM-CONTAINING PHOSPHATE-BINDING DRUGS
DIFFICULTIES IN CORRECTING HYPERPHOSPHATEMIA IN PATIENTS WITH CHRONIC RENAL FAILURE. A PLACE OF NONCALCIUM-CONTAINING PHOSPHATE-BINDING DRUGS

To cite this article:

Milovanov IuS, Fomin VV, Milovanova LIu. Difficulties in correcting hyperphosphatemia in patients with chronic renal failure. A place of noncalcium-containing phosphate-binding drugs. Therapeutic Archive. 2016;88(6):95‑100. (In Russ.)
https://doi.org/10.17116/terarkh201688695-100

МСФ на ЯМ
Close metadata

The review considers the current views of the mechanisms of hyperphosphatemia in patients with chronic renal failure. It shows indications for the use of different classes of phosphate-binding drugs to correct hyperphosphatemia.

Keywords:

chronic renal failure
hyperphosphatemia
fibroblast growth factor 23
Klotho
phosphate-bindings drugs

Authors:

Milovanov Iu.S.

Universitetskaia klinicheskaia bol'nitsa #3 (Klinika nefrologii, vnutrennikh i professional'nykh bolezneĭ im. E.M. Tareeva) Pervogo MGMU im. I.M. Sechenova Minzdrava Rossii

Fomin V.V.

I.M. Sechenov First State Moscow Medical University

Milovanova L.Iu.

Universitetskaia klinicheskaia bol'nitsa #3 (Klinika nefrologii, vnutrennikh i professional'nykh bolezneĭ im. E.M. Tareeva) Pervogo MGMU im. I.M. Sechenova Minzdrava Rossii

List of references:

  1. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: A new paradigm. AJKD. 2000;35(4):117-131.  doi:10.1016/S0272-6386(00)70239-3
  2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009;76(Suppl. 113):S1-S130.
  3. Cannata-Andfaz JB, Rodriguez-Garcia M, Carrillo-Lopez N, naves-Dfaz M, Dfaz-Lopez B. Vascular Calcifications: Pathogenesis, Management, and Impact on Clinical Outcomes. J Am Soc Nephrol. 2006;17:S267-S273. doi:10.1681/ASN.2006080925
  4. Milovanova L, Milovanov Y, Plotnikova A. Phosphorus and Calcium Metabolism Disorders Assosiated with Chronic Kidney Disease Stage III—IV (Systematic Rewiew and Meta-Analysis). Chronic Kidney Disease and renal Transplantation. Ed. by Manisha Sahay. INTECH. 2012;95-118.
  5. Milovanov L.Yu., Nikolaev A.Yu., Milovanov Yu.S. Hyperphosphatemia as a risk factor for cardiovascular disease in patients with chronic renal failure on chronic hemodialysis. Nefrologiya i dializ. 2002;2(4):113-117.
  6. Razzaque MS. Phosphate toxicity: new insights into an old problem. Clin Scie. (Long). 2011;120(3):91-97.  doi:10.1042/CS20100377 
  7. Block G, Klassen P, Lazarus J, Ofsthum N, Lortow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208-2218.
  8. Young EW, Albert JM, Satavathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK. Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67(3):1179-1187.
  9. National recommendations on mineral and bone violations in chronic kidney disease. Russian dialysis society (May 2010). Nefrologiya i dializ. 2011;13(1):33-51. (In Russ.)
  10. Milovanov L, Milovanov Yu, Kozlovskaya L. Phosphorus and Calcium Metabolism Disorders Assosiated with Chronic Kidney Disease Stage III—IV. Klinicheskaya nefrologiya. 2011;1:58-68. (In Russ.)
  11. Berndt Т, Kumar R. Novel mechanisms in the regulation of phosphorus homeostasis. Physiology (Bethesda). 2009;24:17-25.  doi:10.1152/physiol.00034.2008
  12. Oliveira RB, Cancela ALE, Graciolli FG et al. Early Control of PTHand FGF23 in Normophosphatemic CKD Patients: A New Target in CKD-MBD Therapy? Clin J Am Soc Nephrol. 2010;5(2):286-291.  doi:10.2215/CJN.05420709
  13. Milovanova L, Milovanov Yu. Mineral and bone disorders in chronic kidney disease. Prevention and treatment. Ed. Kozlovskaya L. Moscow: Publisher Infra-M; 2014. (In Russ.)
  14. Maltese G, Karalliadde J. The Putative Role of the Antiageing Protein Klotho in Cardiovascular and Renal Disease. Int J Hypertension. 2012;(2012). Article ID 757469. 5 pages http://dx.doi.org/10.1155/2012/757469
  15. Coladonato J. Control of Hyperphosphatemia among Patients with ESRD. J Am Soc Nephrol. 2005;16(11):suppl.2:107-114.  doi:10.1681/ASN.2005060663
  16. Malluche HH, Mawad H. Management of hyperphosphataemia of chronic kidney disease: lessons from the past and future directions. 2002;17(7):1170-1175. PMID: 12105237 [PubMed — indexed for MEDLINE
  17. Tonelli MA, Alan CW, Garg AX, Holdaas H, Jardine AG, Jiang L, Kronenberg F, Parekh RS, Tetsuo S, Walker RJ. KGIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Am J Kidney Dis. 2007;49:S1-180.
  18. Wilkes BM, Reiner D, Kern M, Burke S. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Klin nephrol. 1998;50(6):381-386.
  19. Di Iorio B, Bellasi A, Russo D. on behalf of the INDEPENDENT Study Investigators Mortality in Kidney Disease Patients Treated with Phosphate Binders: A Randomized Study. Clin J Am Soc Nephrol. 2012;7(3):487-493.  doi:10.2215CJN.03820411
  20. Ketteler M, Rix M, Fan S, Prithard N, Oestergaard O, Chasan-Taber S, Guggal A, Kalra PA. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol. 2008;3(4):1125-1130. doi:10.2215/CJN.05161107
  21. Evenepoel P. Control of hyperphosphatemia beyond phosphate. Kidney Int. 2007;71:376-379.
  22. St Peter WL, Liu J, Weinhandl E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis. 2008;51:445-454.  doi:10.1053/j.ajkd.2007.12.002
  23. Vasantha J, Soundararajan P, Vanitharani N, Kannan G, Thennarasu P, Neenu G, Reddy CU. Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis. Indian J Nephrol. 2011;21(4):245-249.  doi:10.4103/0971-4065.83735

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.